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Purpose: To evaluate the diagnostic performance of 18F-flurodeoxyglucose positron
emission tomography/contrast enhanced computed tomography (18F-FDG PET/CT) in
patients with clinically/radiologically suspected ovarian tumor recurrence and normal
tumor markers.
Materials and methods: A total of 54 18F-FDG PET/CT studies from 41 patients with sus-
pected ovarian tumor recurrence and normal tumor markers were evaluated. Each patient
underwent PET/CT with CE-CT scans in the same study. Studies were read independently
by one experienced nuclear medicine physician and one experienced radiologist. A four-
point score (score 0 = definitely benign, score 1 = probably benign, score 2 = probably
malignant and score 3 = definitely malignant) used to assess the presence or absence of
recurrence (local, regional or distant). The final diagnosis of tumor status was made on
the basis of subsequent follow-up by conventional imaging (CT/MRI), 18F-18F-FDG PET/CT
or histopathology whenever possible.
Results: Of the 54 studies evaluated, 26 (48%) studies had tumor recurrence and 28 (52%)
studies were disease-free based on final diagnosis.
Combined 18F-FDG PET/CT vs. CE-CT alone showed sensitivity, specificity and accuracy of
92% vs. 73%, 90% vs. 55%, and 91% vs. 63%, respectively. 18F-18F-FDG PET/CT was signifi-
cantly more sensitive, more specific and more accurate compared to CE-CT with P-values
of 0.06, 0.006 and 0.0001, respectively. Site-based analyses were also performed and
showed significantly higher diagnostic indices for combined FDG-PET/CT.
Conclusion: Combined 18F-FDG PET/CT with contrast enhancement is more accurate than
CE-CT alone in the diagnosis of ovarian tumor recurrence in patients with normal tumor
markers.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ovarian cancer (OC) accounts for 4% of all female can-
cers worldwide; 70% of them present with advanced dis-
ease. OC is the fourth most frequent cause of cancer
death among women [1]. Additionally, OC has a high
propensity for recurrence after therapy. About one fourth
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with advanced disease will ultimately develop a recurrent
disease [2,3].
Patients who have a complete clinical remission are
typically monitored with serial physical examinations
and CA-125 measurements. Serum CA-125 level is a sensi-
tive marker for recurrence in epithelial ovarian tumors.
Rising levels may start 3 to 6 months before clinically
apparent disease.
CA-125 is expressed in more than 80% of serous ovarian
cancers and fewer than 30% of mucinous, clear cell, and
endometrioid OCs [4]. Approximately 85% of patients with
OC have serum CA-125 levels greater than 35 U/mL at the
time of diagnosis [5].
However, it does not provide information concerning
the size and distribution of the lesions. Additionally, CA-
125 levels may increase in a number of benign conditions
and a number of patients with disease relapse may present
with normal CA-125 levels [3].
CT is performed for surveillance of recurrence in clini-
cally suspicious symptoms, abnormalities on physical
examination, or elevated CA-125 levels [6]. However, CT
uses morphologic criteria to detect the disease. Therefore,
accurate detection of intra-abdominal tumor recurrences
may be limited due to difficulties in identifying small
tumor deposits and in separating bowel structures from
adjacent tumor tissue. Also, CT cannot always differentiate
residual viable tumor from post-treatment residual
masses [7].
Second-look laparotomy can detect subclinical disease
in a large group of patients; however, this invasive
approach probably will not affect the patient management
in the absence of potentially curative salvage therapy [1].
Therefore, an accurate non-invasive follow-up method
is still needed for follow-up of OC patients. Integrated
PET/CT employing glucose analog (flouro-deoxyglucose)
has been proven useful in post-treatment surveillance of
OC with reported sensitivity, specificity and accuracy of
73–100%, 40–100% and 63–100%, respectively [8–10].
However, the role of 18F-FDG PET/CT in the setting of
normal CA125 was not clearly defined.
The aim of this prospective study was to compare
the diagnostic performance of whole body diagnostic
contrast enhanced CT (WB CE-CT) and the combined
18F-18F-FDG PET/CT in follow-up of OC with normal tumor
markers.
2. Materials and methods
2.1. Patients
This prospective study recruited patients between
January 2010 and November 2012. All patients had patho-
logically proven ovarian cancer that was treated with ini-
tial standard treatments and referred for post-treatment
surveillance for detection of residual or recurrent disease.
Patients were excluded if they lost to follow-up or had syn-
chronous or past history of other malignancies.
The study was approved by the Institutional Review
Board and each patient signed a written informed consent
form.2.2. PET/CT imaging protocol
The PET with low dose CT and CE-CT imaging protocols
were performed according to the previously published
methods [11].
The 18F-FDG PET/CT scans were acquired using Philips
Gemini time-of-flight PET/CT machine equipped with LYSO
crystals (Philips, Holland). The patients were instructed to
fast for at least 6 h before imaging and their blood glucose
level was measured at the time of the tracer injection and
was less than 200 mg/dl. A dose of 3.7–5.2 MBq/kg was
injected intravenously and adjusted according to patient’s
weight. For the optimal delineation of bowel structures,
400–600 ml of diluted mannitol solution was administered
1 h before CT imaging.
Approximately 60 min after tracer administration, a
low-dose CT scan (5-mm contiguous axial cuts) was
obtained in a 64 integrated multi-slice CT machine, from
the skull base to the mid-thigh. The acquisition was
obtained in a helical mode, using 120 kV, 60 mAs, and a
512  512 matrix size, acquiring a field of view (FOV) of
700 mm in 22.5 s. The first CT scan was used for attenua-
tion correction.
Immediately after the low-dose CT, an emission PET
scan was acquired in a three-dimensional mode over the
same anatomical regions starting from the skull vertex to
the level of the mid-thigh. The acquisition time was
2 min per bed position in 9 bed positions, with a one-
slice overlap at the borders of the FOV. The generated
PET and low dose CT slices were 5 mm in thickness.
Immediately after completing PET acquisition, a diag-
nostic CT with contrast was acquired using 120 kV,
300 mAs, and a 512  512 matrix size. The acquired FOV
was 500 mm using dose automatic modulation in the Z
direction. Non-ionic contrast media was used in a dose of
1–2 ml/kg (maximum 150 ml). Slice thickness was
1.5 mm. The radiation exposure dose from low-dose CT
was in average 3.37 milli Gray (mGy) while that for diag-
nostic CT was 11.48 mGy.
After completion of acquisition, the images were recon-
structed with a standard iterative algorithm, and then the
reconstructed CT attenuation-corrected PET images, low
dose CT images and CE-CT images were transferred to the
viewing stations for reviewing in axial, coronal, and sagit-
tal planes and in a maximum-intensity-projection (MIP)
three-dimensional cine mode using the manufacturer’s
review station (Brilliance, Philips, Holland).
2.3. Data interpretation
For each study, one radiologist and one nuclear medi-
cine physician independently evaluated 11 sites for the
presence or absence of abnormality. The sites were as fol-
lows: local tumor site, peritoneum, pelvic LNs, abdominal
LNs, mediastinal LNs, cervical LNs, liver, lung, bone, brain
and other sites (pleura, muscles, adrenal glands).
First, CE-CT images were interpreted by one radiologist
with knowledge of aim of the study. Any abnormality was
reported according to 4-point score. Score 0 = definitely
benign (e.g. hepatic cyst, adrenal adenoma with low
HFU), score 1 = probably benign (e.g. 1 cm lymph node
Table 1
General characteristics of 41 patients with ovarian cancer and normal
tumor markers.
Parameter n (%)
Patients 41
Age
Median (Range) 54 y. (22–71)*
Pathologic sub-type
Epithelial 40 (98%)
Non-epithelial 1 (2%)
Interval of PET/CT after Therapy ‘‘months” 2 m. (0.25–40)*
Number of studies 54
Treatment modality
Surgery alone 13 (24%)
Surgery + chemotherapy ± RTh 36 (67%)
Chemotherapy alone 3 (6%)
No treatment 2 (3%)
Follow-up
PET/CT 11 (20%)
Clinical/laboratory/other imaging 37 (69%)
Histopathology 6 (11%)
* The numbers in parentheses indicate the range of the data.
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(e.g. 1 cm or less lymph node with lost fatty hilum, peri-
toneal fat stranding and ascites with no nodules) and score
3 = definitely malignant (e.g. the presence of enhancing
solid or cystic nodules or masses of soft tissue/low attenu-
ation, focal, multifocal or diffuse peritoneal thickening, fat
stranding and ascites if associated with peritoneal lesion/
lesions).
Then fused PET/CT with low dose CT was read by one
nuclear medicine physician with reference to the CE-CT
images not the results reported by the radiologist. The rea-
son to use fusion images with low-dose CT rather than
CE-CT is to minimize time interval between CT and PET
acquisitions, consequently, optimizing co-registration of
PET and CT images, especially for mobile structures like
those in abdomen and pelvis. The reason nuclear medicine
physician refer to CE-CT images is to obtain higher tissue
contrast and to better delineate the blood vessels.
Any abnormal 18F-FDG uptake other than the known
normal physiologic bio-distribution was noted and
recorded on the same four point score according to the
possibility of being benign or malignant as follows: Score
0 = definitely benign uptake (e.g. bowel, endometrial
uptake), Score 1 = probably benign (e.g.: reactive lymph
nodes), Score 2 = probably malignant (e.g. abnormal focal
uptake related to bowel but not sure of being definite
peritoneal metastases) and Score 3 = definitely malignant
(e.g. pathologic LN with high FDG uptake).
2.4. Reference standard
The final diagnosis of the presence or absence of recur-
rent/residual disease was made on the basis of subsequent
follow-up by conventional imaging (CT/MRI), tumor mark-
ers, PET/CT and/or clinical follow-up of at least 6 months or
histopathological findings obtained during surgery or
biopsy whenever possible.
Clinical recurrence was defined as the detection of
recurrent disease by CE-CT or a continuously rising
CA-125 level to a value greater than twice the nadir within
6 months of the 18F-FDG PET/CT scan.
2.5. Statistical analysis
Study-based and site-based analyses were employed.
True positive (TP), true negative (TN), false positive (FP)
and false negative (FN) readings were identified based on
subsequent clinical/imaging/histopathological validation.
Diagnostic performance parameters were calculated in
the form of sensitivity, specificity and accuracy. The non-
parametric McNemar test was used to evaluate the statis-
tical significance of the differences in sensitivity and
specificity (two-sided P value < 0.05 was considered signif-
icant) while Receiver’s Operating Characteristic (ROC)
analysis was used to compare the accuracy of the two
modalities.
Quantitative data were summarized and expressed as
mean ± SD, median (range), whereas qualitative data were
expressed as frequencies and percentages. The analyses
were carried out using the SPSS 21.0 (SPSS Inc., Chicago,
Illinois, USA), MedCalc 11.0 (MedCalc, Ostend, Belgium),and Microsoft Excel 2003 (Microsoft, Redmond,
Washington, USA).3. Results
3.1. Patients
A total of 41 patients were eligible. Forty of them
had epithelial tumors (serous: n = 30, mucinous: n = 3,
endometrioid: n = 5 and clear cell: n = 3), and only one
patient had sex-cord stromal tumor. They performed a
total of 54 studies. For the purpose of this analysis each
study was analyzed separately. Patients’ characteristics
are summarized in Table 1.
Of the 54 studies evaluated, 26 (48%) were proved to
have tumor residual/recurrence and 28 (52%) were
disease-free based on final diagnosis.
On study basis, 18F-FDG PET/CT and CE-CT had sensitiv-
ity, specificity and accuracy of 92% vs 73%, 93% vs 57%, and
93% vs 65%; respectively (Table 2).
CE-CT and PET/CT were concordantly TN in 15 studies
(Fig. 1A). PET/CT excluded disease in 11/12 FP studies by
CE-CT (Fig. 1B) with statistically significant difference in
specificity (P = 0.006). Both modalities were TP in 19 stud-
ies (Fig. 1B). Additionally PET/CT diagnosed disease in 5/7
FN studies by CE-CT (Fig. 1A) with no statistically signifi-
cant difference in sensitivity (P = 0.06). The difference in
overall accuracy was statistically significant (P = 0.0001;
Fig. 2A).
3.2. Site based analyses
A total of 594 sites were assessed. Of them, 54 sites
were proved positive and 540 negative of disease. The peri-
toneum represented the most common site for disease
recurrence accounting for 37% of all the positive sites
(n = 20), primary tumor site and pelvic LNs each account-
ing for 17% (n = 9). Abdominal LNs were positive in 9%
Table 2
Diagnostic performances of CE-CT alone and combined with PET/CT from 54 studies in patients with ovarian cancer and normal tumor markers (study-based
and site-based analysis).
Modality FN TP TN FP Sensitivity
95% CI
P Specificity
95% CI
P Accuracy
95% CI
P
Patient-based analysis
All studies CE-CT 7 19 16 12 73 (61–85) P = 0.06⁄ 57 (44–70) P = 0.006⁄ 65 (74–57) P = 0.0001⁄
PET/CT 2 24 26 2 92 (85–99) 93 (86–100) 93 (86–99)
Site-based analysis
All sites CE-CT 28 26 518 22 48 (44–52) P < 0.0001⁄ 96 (94–98) P < 0.0001⁄ 92 (89–94) P < 0.0001⁄
PET/CT 3 51 538 2 94 (93–96) 100 (99–100) 99 (98–100)
Primary tumor site CE-CT 2 7 41 4 78 (67–89) P = 0.5⁄ 91 (84–99) P = 0.6⁄ 89 (81–97) P < 0.2⁄
PET/CT 0 9 43 2 100 96 (90–100) 96 (91–100)
Peritoneum CE-CT 10 10 29 5 50 (37–63) P = 0.008⁄ 85 (76–95) P = 0.06⁄ 72 (60–84) P = 0.0002⁄
PET/CT 2 18 34 0 90 (82–98) 100 96 (91–100)
Pelvi-abd. LNs CE-CT 9 5 92 2 36 (27–45) P = 0.02⁄ 98 (95–100) P = 1.0⁄ 90 (84–96) P < 0.0001⁄
PET/CT 0 14 94 0 100 100 100
Other distant sitesy CE-CT 7 4 356 11 36 (32–41) P = 0.3⁄ 97 (95–99) P = 0.3⁄ 95 (93–97) P = 0.01⁄
PET/CT 1 10 367 0 91 (88–94) 100 100 (99–100)
CI = Confidence Interval
⁄ Statistically significant.
y Other distant sites include mediastinal LNs, liver, lung, brain and bone metastases.
Fig. 1. Schematic representation of the study population categorized according to the results of CE-CT both on patient- (A & B) and site-based (C & D)
analyses in relation to final diagnosis and the changes in diagnoses according to PET/CT.
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6% of the lesions (n = 3). The remaining five lesions were
seen in the liver, bone, lung and abdominal wall muscle.
Overall, PET/CT correctly identified disease in 25 sites
out of 28 that were falsely categorized negative by CE-CT
(Fig. 1C). Additionally, PET/CT excluded disease in 21 out
of 22 FP CT results (Fig. 1-D). The difference in sensitivity,
specificity and accuracy was statistically significant
(Table 2).
For the purpose of analysis, the 11 sites were
re-categorized into 4 groups: primary tumor site,
peritoneum, pelvi-abdominal LNs and other distant sites.3.2.1. Primary tumor site
Both modalities were concordantly TP in 7 and TN in 40
studies. PET/CT diagnosed disease in 2/2 FN studies by
CE-CT and excluded disease in additional 3/4 FP studies
by CE-CT (Fig.1C & D). There was no statistical significant
difference in sensitivity or specificity (Table 2).
3.2.2. Peritoneum
Both PET/CT and CE-CT were TP in 10 studies; however,
PET/CT detected peritoneal disease in 8/10 FN results by
CE-CT (Fig.1C & D) with statistically significant difference
in sensitivity (Table 2).
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modalities in 29 studies. PET/CT excluded disease in all
the FP results encountered with CE-CT (n = 5). There was
no statistical significant difference in specificity. The over-
all difference in accuracy was highly significant (Fig. 2B).
3.2.3. Pelvi-abdominal lymph nodes
PET/CT detected pelvi-abdominal nodal metastases in
all positive sites (n = 14) and excluded disease in all nega-
tive sites (n = 94) (Fig. 1C & D). Statistically significant dif-
ference in sensitivity, specificity and accuracy was noted
(Table 2, Fig. 2C).
3.2.4. Other sites
Eleven sites in this category were considered positive
on final follow-up. Both modalities correctly diagnosedFig. 2. Receiver operating characteristic (ROC) analyses for the diagnostic accura
based on patient- (A) and site-based (B, C, D) analyses.disease in 4 and excluded disease in 356 sites. PET/CT diag-
nosed disease in 6/7 FN studies by CE-CT and excluded
disease in all the FP sites by CE-CT (n = 11) (Fig. 1C & D).
Statistically significant difference in sensitivity, specificity
and accuracy was noted (Table 2, Fig. 2D).4. Discussion
Ovarian cancer tends to present in advanced stages
with high propensity for recurrence. Although specific
guidelines for monitoring disease status after primary
cytoreduction surgery and adjuvant chemotherapy remain
controversial, CA-125 assay remains the most important
surrogate of clinical response and during follow-up [12].
Marker-only recurrence is defined as doubling CA-125
level, either from the upper limit of normal (35 U/mL) incy of CE-CT and combined PET/CT for detecting ovarian tumor recurrence
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ment or from the nadir levels in patients with an elevated
serum marker value that never normalizes after primary
treatment [13,14].
If rising CA-125 is confirmed, CT scan is usually per-
formed. Early treatment is re-introduced for patients with
CT evidence of new or progressive disease. However, in the
absence of clinically or radiographically demonstrable
recurrence, the significance of a rising serum CA-125 level
has yet to be precisely determined [5]. A considerable
interval is usually encountered before development of
symptoms. This interval together with the lack of multiple
treatment options might persuade both the patient and
clinician to delay the treatment especially in the absence
of clear survival benefit for early re-treatment with con-
ventional therapies [15]. However, novel target therapies
for OC are evolving and clinical trials are awaited [16].
With that in mind, early diagnosis of disease relapse could
potentially alter the disease outcome.
PET/CT utilizing metabolic information from FDG has
high diagnostic accuracy in OCs. In this work, we further
documented its superior diagnostic performance in a chal-
lenging sub-group of OC patients with tumor markers less
than 35 U/mL.
In general, our results come in accordance with the pre-
viously reported findings [17–19]. The reported sensitivity,
specificity and accuracy ranged from 86% to 96%, 93% to
100% and 85 to 100%; respectively. However, the work per-
formed by Antunovic et al. [20] reported lower sensitivity
(72%) and specificity (81%). Their retrospective study didFig. 3. A 47-year old female with stage IIIB serous adenocarcinoma underwent cy
after surgery. She was referred for post primary treatment PET/CT 1 month later
foci corresponding to pelvic peritoneal nodule on serosal aspect of sigmoid colon
Both lesions were indistinctive on corresponding CE-CT images (C & D). She und
biopsies and para-aortic lymphadenectomy confirmed positive lesions for metasnot utilize contrast enhancement in the combined PET/
CT. Additionally, conventional imaging (U/S, CE-CT and
MRI) rather than PET/CT was used for follow-up.
In our work, PET/CT significantly outperformed CE-CT.
Only 5 false results were encountered (2 FN and 3 FP) com-
pared to 19 false results for CE-CT (7 FN and 12 FP). One of
the two FN PET/CT studies had non-FDG avid mucinous
cystadenocarcinoma (see Fig. 4), and CE-CT falsely diag-
nosed peritoneal cystic lesion as benign pancreatic cyst.
On follow-up CE-CT, disease progression is identified by
the presence of multiple abdominal and pelvic peritoneal
cystic lesions. The patient received chemotherapy and is
referred for second PET/CT study that showed resolution
of the cystic lesions. The second FN patient did not show
any abnormal metabolic activity but developed peritoneal
metastases 4 months later. It is assumed that microscopic
disease can be missed in peritoneal metastases [21,22].
Two false positive PET/CT studies were encountered.
They were referred less than 1 month after their surgery
which caused increased uptake proved later to be post-
surgical effect. It is known that a clear distinction between
inflammatory and residual disease is hard to achieve
[23,24].
PET/CT successfully confirmed the absence of disease in
11/12 FP CE-CT studies by excluding disease from 21 FP
sites on CE-CT (3 primary tumor, 5 peritoneal, 2
abdomino-pelvic LNs, 7 liver, and 4 lung) (Fig. 1). Similar
results were reported by Sari et al. [19] who showed that
18F-FDG PET/CT correctly excluded recurrence in 8 of 9
patients with normal CA 125 level and positive CT findings.toreduction surgery followed by 6 cycles chemotherapy finished 6 months
with normal CA-125. Axial fused PET/CT images (A & B) showed FDG-avid
(A, single arrow) and small left para-aortic lymph node (B, two arrows).
erwent second look laparotomy 2-months later with multiple peritoneal
tases.
Fig. 4. A 39-year-female with mucinous adenocarcinoma. Axial fused PET/CT images (A & B) showed no abnormal FDG-avid lesions. Corresponding axial
CE-CT (C & D) showed peri-hepatic (single arrow) and peri-splenic (two arrows) peritoneal thickening and scalloping. Combined reading was considered
positive based on the known fact that mucinous adenocarcinoma is frequently non-avid to FDG. A rising tumor marker on follow-up was noted confirming
the diagnosis.
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absence of disease with high confidence in those patients.
Also, PET/CT identified residual/recurrent disease in 5
studies with FN CE-CT findings by correctly localizing dis-
ease in 25 FN sites on CE-CT (2 primary tumor site, 8 peri-
toneal, 9 abdomino-pelvic LNs, 1 mediastinal LN, 3 cervical
LNs, 1 liver, and 1 rectus abdominal nodule) (Fig. 3). It is
assumed that metabolic changes detected by 18F-FDG
PET/CT are readily detectable early before the morphologic
information from CE-CT alone. This group of patients usu-
ally shows progressive low-level increase in CA-125 but
still below normal reference range [25]. Serial CA-125
measurements were not performed in this work and we
did not quantify the rate of increase of CA-125 in relation
to disease status in this work.
PET/CT has the potential to impact the management
decisions in more than half of the patients [26]. In our
results, diagnostic decisions were changed in 30% of
patients (n = 16). However, the effect of this change on
management decisions, quality of life or survival could
not be assessed in this report.
This study has some limitations: relatively small num-
ber of patients, lack of definitive gold standard, and lack
of quantitative change of tumor markers in relation to
timely follow-up. However, some of the advantagesinclude its prospective design and uniform acquisition
and reporting protocol in addition to recruiting a specific
sub-group of ovarian cancer patients with normal tumor
markers which is not frequently reported in the literature.
In conclusion, combined PET/CT with contrast enhanced
CT seems to be effective tool for surveillance of patients
with suspicious OC recurrence and normal tumor markers.
The high false positive and negative rates of CE-CT alone
support the use of 18F-FDG PET/CT as the first imaging
method in those patients. The implications of early discov-
ery of tumor recurrence/metastases on quality of life and
survival need to be validated by prospective clinical trials
probably employing the new target therapies.Conflict of interest
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